1. Choueiri TK, Cheville J, Palescandolo E, et al. BRAF mutations in metanephric adenoma of the kidney. Eur Urol 2012;62:917-922.

2. Dadone B, Ambrosetti D, Carpentier X, et al. A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation? Cancer Genet 2013;206:347-352.

3. Udager AM, Pan J, Magers MJ, et al. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. Am J Surg Pathol 2015;39:549-557.

4. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11-19.

5. Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol 2015;32:400-408.

6. Pinto A, Signoretti S, Hirsch MS, et al. Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. Histopathology 2015;66:901-904.

7. Chami R, Yin M, Marrano P, et al. BRAF mutations in pediatric metanephric tumors. Hum Pathol 2015;46:1153-1161.

8. Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol 2010;34:1608-1621.